
Q&A: Tillman Gerngross explains why his Covid mAb will have an edge over an already crowded field
If anyone knows about monoclonal antibodies, it’s serial entrepreneur, Adimab CEO, and Dartmouth professor of bioengineering Tillman Gerngross.
Even the name of Gerngross’ new antibody startup Adagio Therapeutics is meant to reflect his vision behind the development of his Covid-19 mAb: slowly, he said, explaining that “everyone else, whether it’s Regeneron, Lilly, or AstraZeneca, Vir, they all valued speed over everything.”
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.